Physician profile
Corey Cudzilo
NPI 1003012022
$4,360.88
in general payments reported to CMS, 2019-2025
24 companies · $631 in 2025
The $631 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,784 · 2020: $187 · 2021: $190 · 2022: $153 · 2023: $939 · 2024: $477 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.00 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,132.51 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $941.19 | 2019-2025 | Tezspire, Fasenra |
| Amgen INC. | $465.21 | 2023-2025 | Tezspire |
| Pfizer INC. | $205.78 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $182.19 | 2019-2024 | Xarelto |
| Csl Behring | $168.61 | 2019-2024 | Kcentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.26 | 2019-2023 | Ofev |
| Electromed, INC. | $160.00 | 2019 | |
| Abbvie INC. | $157.80 | 2021-2025 | Dalvance, Avycaz |
| Abbott Laboratories | $145.99 | 2025 | 2nd Gen Centrimag Primary Console |
| Regeneron Healthcare Solutions, INC. | $144.24 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $133.26 | 2019-2024 | Nucala |
| United Therapeutics Corporation | $72.23 | 2021-2022 | |
| Ucb, INC. | $56.04 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $40.57 | 2022-2023 | Ultomiris |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $34.29 | 2019 | |
| Genentech USA, INC. | $31.93 | 2020-2021 | |
| Allergan, INC. | $23.76 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.61 | 2025 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $18.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.05 | 2020 | |
| Jazz Pharmaceuticals INC. | $15.88 | 2019 | |
| Philips North America LLC | $15.68 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Cudzilo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.